BOSTON – October 11, 2017: The cognitive science company, Cogstate today announced the commercial deployment of its Cognigram™ digital cognitive assessment system at the University of Notre Dame. This placement represents the first Cognigram system commercial implementation in the United States, following the recent FDA notification that the Company can begin marketing the system in the U.S.
“We are thrilled that the University of Notre Dame decided to adopt our cognitive testing solution immediately after the Cognigram system became available in the U.S.” said Frank Cheng, President of Cogstate Healthcare. “We look forward to supporting the University of Notre Dame in their concussion management programs for RecSports.”
The Cognigram system is a digital cognitive assessment tool with self-administered assessment that can be completed both in-clinic and at-home. It is for prescription use, and is intended to aid healthcare professionals with an objective measurement of cognition for use in individuals aged 6 – 99 years old. The Cognigram system can be used to assess cognition on a single occasion or cognitive change over periodic assessments. Performance on the Cognigram system is unaffected by language, education, cultural background, or repeat practice.
Factors that may affect an individual’s cognition include the presence of mild cognitive impairment (MCI), Alzheimer’s disease, concussion, head injury, major depressive disorder, HIV related dementia, schizophrenia, attention deficit hyperactivity disorder (ADHD), multiple sclerosis, Parkinson’s disease, the effects of medication or surgery, as well as a variety of psychological states (e.g. stress, fatigue).
